Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate

Medicago/GSK announce Ph 3 trial start of Medicago’s plant-derived COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant.